Ibuprofen Suspension Brand Ranking

Renfu Pharmaceutical Group Co., Ltd.

Renfu Pharmaceutical Group Co., Ltd. was established in 1993 and listed on the Shanghai Stock Exchange in 1997. It is the leading pharmaceutical industry enterprise in Hubei Province's National Enterprise Technology Center, a national technological innovation demonstration enterprise, and a leading enterprise in the internationalization of Chinese pharmaceutical enterprise preparations. Domestic narcotic drugs, steroid hormone drugs, Uyghur ethnic medicines have established a leading position in many sub-sectors. The company is mainly based on the pharmaceutical industry and supplemented by the pharmaceutical business, and is steadily promoting internationalization. The pharmaceutical industry has achieved full dosage form production capacity of pharmaceutical intermediates-raw materials-pharmaceutical excipients-pharmaceutical preparations in the entire industry chain; pharmaceutical business adheres to the positioning of "comprehensive medical service supplier", lays out commercial networks, and achieves full regional coverage; internationalization has formed The full value chain capability of pharmaceuticals for global R&D, registration, production and sales has been exported to more than 80 products in more than 70 countries and regions around the world. Based on innovative drugs, innovative preparations and high-end generic drugs with high clinical value, the company aims at cutting-edge fields and creates a first-class innovative R&D industrialization platform. R&D centers have been set up in Wuhan, Yichang, China, New Jersey, St. Louis and other places in the United States. The group has more than 500 projects under development, including more than 30 new drugs in Class I, and has obtained 778 authorized patents. Renfu Pharmaceutical firmly adheres to the development strategy of "being a leader in the pharmaceutical market segment". Through the three strategic paths of "focusing, innovation, and internationalization", it gradually realizes the leap from international follow-up to leading, and creates global competitiveness. a world-class pharmaceutical company.

ZHANGJIAGANG WELLHOW TRADING CO., LTD.

Our Company is located in Zhangjiagang City of Jiangsu Province, whichis 90 minutes` drive from Shanghai. We started yarn business with Ludhiana market from the year of 2000.With the rapid annual growth of the business. Our total sales will reach 16million US dollars this year. We can make and supply all kinds of Yarns, and specialize in feather yarn, mink yarn, core spun yarn . Best price, Good quality, Customers satisfactions are our primary target. Contact details: Add: Rm.8605, Chenlong Building, No.288 Jingang Avenue, Zhangjiagang, Jiangsu, China. Tel: 86-512-58987376 Mobile No.: 86-13901563309 Post Code: 215600 E-mail: lxl@wellhowtrade.com

Xuzhou Seagor Import And Export Co., Ltd.

Seagor is founded in 2015.It belongs to Xuzhou xinchang company and mainly responsible for export . Xuzhou Xinchang Textile Co.,Ltd was founded in 2007.The company are located in Jiangsu Province.It has the convenient transportation and good industrial envirnment.It is engaged in the development,Production and Sales for Chemical Fiber,Natural Fiber and Various Yarns.The advanced production equipment help xinchang from a small family workshop to a leader in yarn field. We also have almost 25 factories which we are long time cooperated with. Our main productions are Chemical Fiber,Natural Fiber and Various Yarns.We supply Color Spun Yarns,Bamboo Yarns and Covering Yarns.The main composition are polyester,polyester cotton blend ,polyester viscose blend ,viscose etc.Colors will meet the demands for customers. Our main market is Brazil, Mexico, Argentina, Ecuador, Dominica, Bolivia, Chile, Russia, Belarus, Uzbekistan, Kazakhstan, Mongolia, Romania, Poland, Armenia, Ukraine, India, Pakistan,Thailand, Vietnam, Malaysia, Indonesia and so on Our production capacity: 2 * 40HQ per day; Our quality standard: can do quality certificate, like SGS Our price promise: lower than market price In Seagor, competitive price , good quality ,best lead time ,good service.

Wuxi WenqiIndustry and Trade CO.,LTD.

Wuxi Wenqi Industry and Trade Co., Ltd. has devoted itself to providing various reflective filaments, reflective strips, reflective cloth, reflective film, reflective crystal lattice, reflective leather, reflective ribbon, etc. for fashion, labor insurance, professional wear, children's wear, sanitation, action, leisure, shoe industry, antistatic, electronic, textile fabrics, etc. with an infinite vigor and ideal young team. Transfer Printing, Reflective Printing, Thick Plate Transfer Printing, Silica Gel Label, Drop Plastic Label, Silica Gel Transfer, Drop Plastic Transfer, Laser Processing and other products and services. Wenqi Industry and Trade is a new garment accessories company with modern flavor. After years of development, our sincere friend now covers an area of nearly 1000 square meters, more than 20 technicians, nearly 7 years of garment industry service experience, has a complete set of high-frequency machinery processing equipment, with strong capacity, perfect quality management, advanced and mature production technology, committed to creating products for you. We have been pursuing the road of professional development, always adhering to the operating principle of "quality di first, customer first, innovation and development". Through continuous improvement, we have always mastered the precise core technology, exquisite manufacturing technology and product quality control, and used our professional services to help customers create higher value. We believe that through our continuous efforts and pursuit, we will be able to achieve mutual benefit and win-win with our customers!

Johnson & Johnson (China) Investment Co., Ltd.

In 1995, Johnson & Johnson, the United States established a pharmaceutical company specializing in the production of self-health drugs in Shanghai - Shanghai Johnson & Johnson Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanghai Johnson & Johnson Pharmaceutical"). Through continuous innovation, Shanghai Johnson & Johnson Pharmaceutical provides high-quality products to patients and consumers in the fields of colds, coughs, fever, pain, allergies, etc. The company's products have been recognized by professional medical staff and pharmacists. A series of products that have been successfully launched so far have been widely known and recognized by patients and consumers, including: Tylenol (Phenol Amemin Tablets/Phenol Amemin Suspension), Tylenol Norin (acetaminophen sustained release tablets), Tylenolin (acetaminophen suspension drops/acetaminophen oral suspension), Merrillin (ibuprofen suspension/ibuprofen suspension Drops), Aishu (Yu Pseudo-Masume oral solution/dextromethorphan guaifene ether syrup) and Aishu (Psychological Masumethorphan drops), Helifuting (levocasubastin hydrochloride nasal spray), etc. . The company has always adhered to a high level of professional ethics and its commitment to improving the quality of life of the public. Johnson & Johnson Pharmaceutical insists on taking social contributions as its mission, actively participates in social welfare undertakings, and continues to donate to disaster areas, poor areas, etc. through various social welfare groups, so as to transform the belief in corporate social responsibility into practical actions.

Tian Da Pharmaceutical Co., Ltd.

Tianda Pharmaceutical Co., Ltd. (hereinafter referred to as Tianda Pharmaceutical, a listed company on the Hong Kong Stock Exchange, stock code 0455) is based on the development of the traditional Chinese medicine industry, develops innovative drugs and medical technology, develops high-quality medical and health care services, and is committed to becoming a pharmaceutical product. Pharmaceutical companies with market competitiveness and core value chains in the fields of research and development, medical technology, traditional Chinese medicine diagnosis and treatment, and health management. Tianda Pharmaceutical has built a full traditional Chinese medicine industry chain from the three aspects of traditional Chinese medicine, traditional Chinese medicine and traditional Chinese medicine intelligence, established the "Tianda Standard" to control the quality of traditional Chinese medicine materials, and established a new Chinese medicine clinic - Tianda Pavilion. As a platform for traditional Chinese medicine diagnosis and treatment and health management, Tiandaguan adheres to the traditional Chinese medicine concept of "preventing diseases before they are sick", adheres to the treatment principle of "stop diseases when they are sick, and people-oriented", is based in the Guangdong-Hong Kong-Macao Greater Bay Area, and is located in the whole country and globally, striving to develop into traditional Chinese medicine The first brand of the museum; and make full use of Internet information technology, big data, artificial intelligence and other innovative technologies to build a "Cloud Heaven Hall" to realize the integration of online and offline traditional Chinese medicine services, remote diagnosis and treatment and expert consultation, and provide the public with High-quality, convenient and comprehensive traditional Chinese medicine health services have become the leader in promoting the inheritance, innovation and development of traditional Chinese medicine. Tianda Pharmaceutical focuses on the development of global pharmaceutical and health technology and the latest achievements, continuously increases R&D investment, strengthens innovation, accelerates technological progress, optimizes product structure and improves service levels, and forms a sustainable competitive advantage. The company's products include traditional Chinese medicine, chemical drugs, biological products, health products and medical devices, etc., covering the fields of cardiovascular, pediatrics, colds and respiratory, anti-infection, anti-addiction, anti-tumor and other therapeutic drugs, as well as "Hegu" , "Tokang" brand series of health products, etc. Tianda Pharmaceutical relies on the Chinese market, strives to expand the international market and build a global marketing network. The company has set up marketing centers in Shenzhen and Zhuhai, China, responsible for sales and brand building in the Chinese market. Through distributors and terminal retailers in various provinces, cities and regions, products are sold well all over the country; established wholly-owned subsidiaries in Hong Kong and Australia, and gradually Establish branches in the United States and Europe, responsible for sales and brand building in Hong Kong, Macao, Australia and international markets. Tianda Pharmaceutical is guided by market demand, expands medical and health care services, and works with high-quality domestic and foreign partners to integrate advanced treatment and health care technologies to build a global health examination, health management, health consultation and chronic disease prevention and control system to meet the growing , different levels of medical and health care needs to better protect the health and well-being of the general public. Your health is a big deal! This is the vision and slogan of Tianda Pharmaceutical, expressing Tianda Pharmaceutical's desire and pursuit to continuously contribute health and care. Taking this as a driving force, Tianda Pharmaceutical strives to develop into a leading pharmaceutical company based in China and radiates to the world.

JIANGYIN ZHONGXIE NEW MATERIAL CO.,LTD

Established in 1988, Zhongxie Group has been adhering to the tenet of being guided by science to pursue excellence" and taking the purpose of high-quality development to become a world-class chemical enterprise. Now we have 4 factories in China ,1 factory in Vietnam ,1factory in Egypt and 1 line in Egypt. Zhongxie group has below factories :Jiangyin Changshou Chemical Fiber,Jianyin Zhongxie New Material Co.,Ltd,Wuxi Xichuang Innovative Materials Co.,Ltd,Haolin New Material Technology Co.,LTD ,The Group takes the polyester industry as the main business and concurrently develops polyester staple fiber , spun yarn, and spunlace non-woevn fabrics ,fialment etc .

Xiangyu Pharmaceutical Co., Ltd.

Xiangyu Group was founded in 1986 and has gone through five stages and four transformations. It has now developed into a modern pharmaceutical enterprise. The main industries of the enterprise are among the top 100 in the country. Xiangyu Pharmaceutical mainly produces gynecological drugs represented by compound red blood replenishing oral liquid, pediatric drugs represented by Xiangma Hanpan patch, psychotropic drugs represented by Mianselin hydrochloride, and Yishen Granules. 11 types of preparations such as tonic medicine, with more than 200 varieties and more than 300 product specifications, and are committed to creating a "first-line brand of Chinese maternal and child medicine". The company invests no less than 10% of its sales revenue each year in scientific and technological research and development, and has successively established scientific research platforms such as the National Enterprise Technology Center, Academician Workstation, Postdoctoral Research Workstation, and New Gynecological Drug Preparation Engineering Research Center.

Beijing Hanmi Pharmaceutical Co., Ltd.

Beijing Hanmei Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Hanmei) was established in March 1996 and is located in the beautiful environment of Beijing Shunyi Airport Development Zone, covering an area of ​​13,600 square meters. In addition to its headquarters, Beijing Hanmei also has a research center, a GMP factory and a sales team all over the country. In 2008, it established an international "Business Center" (Business Center) with an international level, integrating "R&D, Production, and Sales". Located in one. Among them, the GMP factory was carefully designed and built strictly in accordance with the GMP standards. It passed the GMP certification of the State Administration of Drug Administration for the first time in December 2001 and officially put into production and use, and passed the new version of the GMP certification at the end of 2015. The research center has an area of ​​nearly 4,000 square meters, including biological laboratories, chemical synthesis laboratories and pharmacological toxicology laboratories. It is equipped with a variety of international drug research equipment, and is equipped with advanced foreign research and development centers, Korean and American pharmaceutical headquarters, Korean and American fine chemical engineering The factory and formula R&D center work closely together to form a global R&D network. The sales team covers all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties in China. The company's product business involves pediatric products, gastroenterology products, orthopedic products, anti-infective drugs and other fields. 98% of the products are produced in China. The main products include Mommy Ai, Yi Tanjing, Yi Anping, Mei Chang'an, Li Dong, and Vinegar. More than a dozen varieties such as clofenac and Ruimai. Among them, Mommy Ai and Yi Tanjing have become basic regular medicines for children in China and are very popular among doctors and children's parents. In 2019, Mommy Love launched a series of probiotic infant and toddler cleaning products to help Chinese babies have healthy skin and to take care of the healthy growth of infants and toddlers. 2021 marks the 25th anniversary of the establishment of Beijing Hanmei Pharmaceutical Co., Ltd. In July of the same year, the company invested 300 million yuan to build a new intelligent automation warehouse with an area of ​​about 1,800 square meters and a pharmaceutical workshop known as "having a large domestic oral liquid production line". The completion and opening marks a new step in the industrialization development of Beijing, South Korea and the United States.

Shandong Xinhua Pharmaceutical Co., Ltd.

Shandong Xinhua Pharmaceutical Co., Ltd. was established in 1943 in Jiaodong Anti-Japanese Base Area. It is an early chemical synthetic pharmaceutical enterprise in New China. It is an important global production and export base for antipyretic analgesics and painkillers. It is an important domestic cardiovascular and anti-infection. Manufacturers of nervous system, steroid hormone drugs, etc. It has four major business segments: chemical raw materials, pharmaceutical preparations, pharmaceutical intermediates, and e-commerce business, 5 industrial parks and 14 subsidiaries. The annual production capacity of chemical raw materials is 50,000 tons, 500,000 tons of pharmaceutical intermediates, 32 billion solid preparations (particles), and 1.5 billion injections. The annual export volume is nearly US$400 million, and it has established long-term strategic cooperative relations with more than 200 well-known multinational companies including Roche, Bayer, and Bailey. Xinhua Pharmaceutical is a listed company in H-share and A-shares. Xinhua Pharmaceutical is a national high-tech enterprise, a key high-tech enterprise of the National Torch Plan, and a backbone enterprise of the National Torch Plan biopharmaceutical industry base. It has a national enterprise technology center, and has academician workstations, postdoctoral workstations, Taishan industrial talent positions, Taishan scholar positions, There are six major talent platforms including the Master's Joint Training Point and Shandong Technician Workstation. In recent years, Xinhua Pharmaceutical has increased its school-enterprise cooperation efforts and established comprehensive strategic cooperative relations with the Chinese Academy of Medical Sciences, Tsinghua University, Shandong University, Shenyang Pharmaceutical University, Qingdao University of Science and Technology, etc. Six centers including the Medicinal Chemistry Research Center and the Drug Preparation Research Center have been built, covering 12 directions including digestive system, pain control, cardiovascular and cerebrovascular system, anti-metabolic system, nervous system, nutritional health, hormones, etc. , increase R&D investment and lay out more than 100 new products. A total of 21 products and 27 specifications have passed consistency evaluation, and have 8 national first-class new drug documents and 21 second-class new drug documents and obtained 266 authorized patents. It is a three-star "Chinese Patent Shandong Star Enterprise". Xinhua Pharmaceutical's quality value of "product quality is related to the life of the enterprise, and drug quality is related to the life of the person" has been thoroughly implemented by all employees and throughout the process. The company focuses on quality investment and has established a quality control system for the entire process from the entry of raw materials into the factory and the production link to the exit of the product. In the 1990s, Xinhua Pharmaceutical won the domestic "Excellent Quality Management Award". 23 products have won high-quality product awards at the provincial and ministerial levels and above, of which 3 products have won the national gold award and 3 products have won the national silver award. At present, all drugs in production in Xinhua Pharmaceutical have passed the national new version of GMP certification, and have obtained 22 US FDA registration documents, 12 EU EDQM documents, and 3 ANDA documents. Xinhua Pharmaceutical Modern Pharmaceutical International Cooperation Center has passed the China NMPA, GMP certifications such as the UK MHRA, the US FDA and the EU, the preparation products produced by the center are qualified to be sold to international markets such as Europe, the US and the UK, and have exported more than 5 billion tablets in total. In recent years, Xinhua Pharmaceutical has launched a batch of new drugs such as: National Class I innovative drugs, new non-hormonal anti-inflammatory and anti-allergic drugs----------------------------------------------------------------------------------- Shutaide (rabeprazole sodium enteric-coated tablets), Jiaheluo (glimediide tablets), the drug for treating cardiovascular and cerebrovascular treatment (aspirin enteric-coated sustained-release tablets), the National Class 3.1 new drug insurance Chang (Jocal calcium tablets), Fuya'an series three high-purity fish oil health products, and unique dosage form nimodipine sustained-release capsules, the main products are included in the national medical insurance catalog. As a state-owned holding enterprise with red gene, Xinhua Pharmaceutical has always adhered to the corporate mission of "protecting health and benefiting society" and actively fulfilled its social responsibilities. Especially in the three years of fighting the epidemic, Xinhua People do not uphold conditions, live up to their mission, and do their best to do their best. Production and supply of drugs. Especially since the adjustment of the epidemic prevention and control policy in December 2022, the national allocation task was successfully completed in just over 20 days, and a total of 800 million pieces of ibuprofen and other heat-relieving towns were supplied to 31 provinces (municipalities directly under the central government, autonomous regions) across the country. Pain drugs (most of the ibuprofen tablets in the Beijing market are supplied by Xinhua Pharmaceuticals) have effectively guaranteed the people's drug needs and truly reflected the responsibility of state-owned enterprises. The Ministry of Industry and Information Technology, Beijing, Tsinghua University, Fujian Province, Nanjing, Dalian, Yangzhou City and other cities have successively sent letters of condolences and thanks to Xinhua Pharmaceutical, giving high recognition and praise for Xinhua Pharmaceutical's full efforts to ensure the supply of key drugs for the epidemic. Over the years, the company has highlighted the connotation of quality, internationalization, science and technology and responsibility, and has created professional characteristics through all-round means, establishing a good image of quality Xinhua, international Xinhua, science and technology Xinhua and responsibility Xinhua. Xinhua Pharmaceuticals was listed in Shandong Province's first batch of "Honorable Shandong Business" five-star brand image list, and won the National Model Labor Relations Harmonious Enterprise, National Green Factory and Green Supply Chain Enterprise, China Quality Integrity Enterprise, Shandong Province All Staff Innovation Enterprise, Shandong The provincial talent work unit, the leading science and technology enterprise in Shandong Province, and the Shandong Province's advanced collective in fighting the new crown pneumonia epidemic are honored.

Shaoxing Shujin Chemical Fiber Co.,Ltd.

Established in 2005,Covering an area of 50000 square meters, Shaoxing Shujin Chemical Fiber Co Ltd is a professional manufacture that is concerned with the design,development and production of covering yarns. Main production are spandex covered yarn,rubber covered yarn.We are located in Shaoxing City which has a developed economy and beautiful scenery,with international quality standards and are greatly appreciated in a variety of markets around the world.

Jiangsu Hengrui Medicine Co., Ltd.

Founded in 1970, Hengrui Medicine is an international pharmaceutical company engaged in the development and promotion of innovative and high-quality drugs. It focuses on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases, cardiovascular diseases and other fields. For many years, Hengrui Medicine has always been rooted in China and facing the world, focusing on health, focusing on cutting-edge fields, and overcoming difficulties to promote high-quality development of the pharmaceutical industry. The company regards scientific and technological innovation as its first development strategy and continues to invest in R&D with high intensity. The company has invested a total of 23.8 billion yuan in R&D in the past decade, of which 6.203 billion yuan of R&D investment in 2021, and the proportion of R&D investment in operating income reached 23.95%, ranking The forefront of the industry. The company has successively established R&D centers or branches in Lianyungang, Shanghai, Chengdu, the United States and Europe, and has built a global R&D team with a scale, professional and comprehensive capabilities of more than 5,000 people. At present, the company has 12 innovative drugs including reverutamide, hitrapopal, carrilizumab, etc., and the first new drug introduced by the company has also been approved for marketing. This is also the company's external cooperation. Among the products, more than 60 innovative drugs are being clinically developed, and more than 260 clinical trials are being carried out at home and abroad. The company has rich R&D pipelines. In addition to the traditional advantageous tumor field, it also prospectively and widely deploys multiple therapeutic areas such as autoimmune diseases, pain management, cardiovascular diseases, and metabolic diseases. The company has also established a number of new technology platforms with independent intellectual property rights and internationally advanced to provide strong basic guarantees for innovation and research and development. As of the end of 2022, the company has applied for 2,064 invention patents, 583 PCT patents, 507 valid domestic invention patents, and 618 authorized patents from Europe, America, Japan and other countries. The company continues to steadily promote internationalization. As of the end of 2021, Hengrui Pharmaceutical products have entered more than 40 countries, and are continuing to accelerate the development of global markets and focus on emerging markets. The company insists on both independent research and development and open cooperation, and strengthens international cooperation on the basis of endogenous development. Through cooperation with American and Korean companies, the company authorizes innovative drugs with independent intellectual property rights such as SHR2554, carrilizumab, SHR0302 to the public. In addition, Hengrui Medicine has obtained more than 20 registration approvals including injections, oral preparations and inhaled anesthetics in Europe, the United States and Japan, improving the accessibility of drugs in patients in different regions around the world. Perseverance leads to a long-term future, and a prosperous life. In the future development, Hengrui will continue to adhere to the mission of "technology-based, creating a healthy life for mankind", with the vision of "focusing on innovation and building a multinational pharmaceutical group", accelerate technological innovation, and strive to develop more new drugs, Good medicines benefit patients and better serve healthy life!

Yangzhou Sanyao Pharmaceutical Co., Ltd.

Yangzhou Sanyao Pharmaceutical Co., Ltd. is located in Yangzhou City. It has now become a modern national high-tech enterprise integrating pharmaceutical research and development, pharmaceutical production and marketing. The company covers an area of ​​190,000 square meters, a building area of ​​85,000 square meters, and a greening area of ​​61%. It produces ten dosage forms such as suspensions, tablets, capsules, granules, mixtures, oral solutions, syrups, and raw materials. There are more than 70 varieties in total, and it is a modern production base designed and built in accordance with the requirements of GMP and has a large number of products. The company introduced production and quality testing equipment with advanced domestic level and a scientific and rigorous production and quality control system, which has brought the company's production scale and product quality to a new level, and has fully demonstrated the vitality of Yangzhou Sanyao. The research and development of Yangzhou Sand Pharmaceuticals is market-oriented, with the goal of serving the society and creating health, focusing on innovative drugs with broad market potential. The company has formed a strong R&D team to independently develop with its own technology. The research and development of new products has provided strong impetus for the company's sustainable and stable development. At present, the company has a strong product portfolio of more than 70 drugs, focusing on the treatment areas of cardiovascular, anti-infection, gastrointestinal tract, respiratory tract, neurological and other diseases. Including the first-class national drug and the new generation of fluoroquinolone anti-infective drug Gatifloxacin mesylate capsule (Tianxin). The main products include Tianqian (ibuprofen suspension), Shuangchang (ambroxol hydrochloride) tablets and oral solutions, Rifaximin dry suspension (Qianerfen), Tramadol hydrochloride granules, metformin hydrochloride Glibenbutyric tablets, clarithromycin capsules, Junyi (Trazosin hydrochloride capsules), simvastatin capsules, etc. The raw materials include ambroxol hydrochloride, alanylglutamine, methonamide hydrochloride, ornizole, saxagliptin, etc.

Yangzhou Yiyang Pharmaceutical Co., Ltd.

Yangzhou Yiyang Pharmaceutical Co., Ltd. is located in Gaoyou Economic Development Zone, Jiangsu Province, covering an area of ​​nearly 100 acres. It is a modern pharmaceutical enterprise established on June 28, 1994 by South Korea Yiyang Pharmaceutical Co., Ltd. and Gaoyou Industrial Corporation. The company officially started production on July 8, 1998. In the same year, the three production lines of powder injection, tablets and suspensions all passed the national GMP certification, and are one of the enterprises in the country that have passed the national GMP certification. The main products include a unique new type of neutralizing gastric acid drug aluminum magnesium plus suspension ("Anda"), ibuprofen suspension, and a compound treatment for symptoms caused by insufficient bile secretion or lack of digestive enzymes. Zimmite enteric-coated tablets ("Mitte"), powder injection lysin ("Asagir", imported raw material) and other products. The main production equipment of the preparation workshop is introduced from Italy, South Korea, etc., with complete testing equipment, with hardware conditions that match the production products and a complete quality assurance system. The product sales network covers the whole country. Over the years, the company's operations have been operating healthily and healthily. In order to meet the continuous market demand, the company invested nearly 100 million yuan in 2013 to implement technical transformation. From September 2014 to May 2015, a new comprehensive preparation workshop (powder injection workshop and tablet workshop are built. , inspection center and warehousing, etc.) have passed the GMP (2010 version) certification and put into production; a new suspension workshop will be built in September 2018, and it is expected to be put into production and use in 2020. While the production scale continues to expand, the company has cooperated with foreign parties to develop a number of new products such as anti-leukemia drugs according to market needs, and R&D work is underway.

Prestige Consumer Healthcare

PediaCare specializes in children's healthcare products, including ibuprofen suspension, designed to relieve pain and reduce fever in children.

Perrigo Company

Perrigo offers a generic ibuprofen suspension, providing an affordable alternative for pain and fever management.

Reckitt Benckiser

Nurofen is a popular ibuprofen brand available in various formulations, targeting specific types of pain such as headaches, muscle aches, and joint pain.

Teva Pharmaceuticals

Teva's ibuprofen oral suspension is a generic option known for its effectiveness in treating mild to moderate pain and inflammation.

Walgreens

Walgreens offers pediatric ibuprofen drops, a convenient and effective solution for managing pain and fever in young children.

Sun Pharmaceutical Industries

Sun Pharma's pediatric ibuprofen suspension is designed to provide safe and effective pain and fever relief for children.